Welcome! Login | Register
 

Central MA’s 2015 College Commencement Speakers—Central MA's 2015 Commencement Speakers

Monfredo: Worcester - The City That Reads is in Need of Additional Books—The kick off for the tenth annual book…

Worcester’s Dimitri M.D., Named President of MA Medical Society—Worcester's Dimitri M.D., Named President of MA Medical…

Revolution Unbeaten In Seven-Straight, Win 2-1 Over New York—The New England Revolution continue their early season…

Patriots Make Two Selections On Second Day Of NFL Draft—The New England Patriots selected Jordan Richards and…

Fit For Life: Get Fit For Fun—Now that it's nice out, you’re thinking to…

Sharks Season Comes to End With 10-4 Loss to Hershey—Sharks Season Comes to End With 10-4 Loss…

Leonard Moorehead, the Urban Gardener: Asparagus at Last—Urban gardeners are a motley crew. Whether a…

Beauty Insider: Mother’s Day Gifts - Palettes to Make Mom Pretty—Old-world glam in a modern package

Make the Most of Your Home’s Equity—Now that spring has finally sprung in New…

 
 

AG Announces $68.5 Million Settlement with AstraZeneca

Friday, March 11, 2011

 

Attorney General Peter Kilmartin announced today that a $68.5 million dollar settlement has been reached with AstraZeneca Pharmaceuticals.

This settlement, which is the largest ever multi-state consumer protection-based pharmaceutical settlement, is expected to bring $908,838 to the state.

The settlement stems from a complaint alleging that AstraZeneca used deceptive practices to market the antipsychotic drug Seroquel for off-label uses, according to the Attorney General. The company was accused of withholding information on the drug’s dangerous potential side effects, in addition to the negative results of scientific study done that tested the safety of the drug.

“This settlement shows the commitment of this office to protect consumers from deceptive marketing and advertising practices by big pharmaceutical companies,” Kilmartin said.

Company promises changes

AstraZeneca has promised to alter the way that it markets Seroquel, eliminating the misleading practices in question. Along with the $68.5 million payment, under the settlement AstraZeneca must comply with provisions addressing numerous concerns that an extensive 3-year investigation yielded. For example, AstraZeneca must have policies in place to ensure that sales personnel do not promote to health care providers who are unlikely to prescribe Seroquel for an FDA-approved use.

Other states participating in the investigation and settlement were: Florida, Illinois, Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Idaho, Iowa, Kansas, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Vermont, Washington, West Virginia and Wisconsin.
 

 

Enjoy this post? Share it with others.